Shortness of breath; Congestion nasal; body aches; occational cough; occational chills; weakness; Totally Exhausted /Fatigue; Interchange of vaccine products/revaccination With different covid-19 vaccine; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 20230336631 (Janssen).  A 66-year-old male patient received BNT162b2 (BNT162B2), on 17Feb2022 as dose 2 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: janssen coviD-19 vaccine (DOSE 1, SINGLE, Anatomical location: left arm), administration date: 29Apr2021, for Covid-19 Immunisation, reaction(s): "Loosing 9 units of blood/ Excessive Bleeding", "Blood mixed with his own feces", "Uncontrolled Bowel Movement", "Lost Control with his bladder", "Irregular Appetite", "Shortness of Breath", "Congestion", "Body Aches", "Occasional Cough", "Occasional Chills", "Weakness". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 17Feb2022, outcome "unknown", described as "Interchange of vaccine products/revaccination With different covid-19 vaccine"; FATIGUE (non-serious) with onset 13Mar2023, outcome "not recovered", described as "Totally Exhausted /Fatigue"; DYSPNOEA (non-serious), outcome "not recovered", described as "Shortness of breath"; NASAL CONGESTION (non-serious), outcome "not recovered", described as "Congestion nasal"; PAIN (non-serious), outcome "not recovered", described as "body aches"; COUGH (non-serious), outcome "not recovered", described as "occational cough"; CHILLS (non-serious), outcome "not recovered", described as "occational chills"; ASTHENIA (non-serious), outcome "not recovered", described as "weakness".  Sender's comments: loosing 9 units of blood / excessive bleeding, uncontrolled bowel movements, blood mixed with his own feces, lost control with his bladder, irregular appetite. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. Therefore, the WHO Causality is considered indeterminate. The company causality is considered unassesable.  Additional information: On unspecified date in 2021 (reported as 5 weeks after shot) the patient experienced adverse effects loosing 9 units of blood/ excessive bleeding, irregular appetite (dose number in series 1). He had uncontrolled bowel movements, prone in hospital bed for 3 days with his blood mixed with his own feces and Lost control with his bladder (dose number in series 1). The patient was treated with some plasma. He survived it. He said those are residual effects from loosing of 9 units of blood or side effect from vaccine. On an unspecified date, he reported further symptoms of shortness of breath, fatigue, congestion, body aches, no diarrhea, no nausea, occasional chills, occasional cough (Dose number i r. series 1) . He never lost sense of taste or smell, no sore throat. He knew his symptoms and enough about his body, residual symptoms had to be connected in some way. His body had not righted itself in 2 years. He was still facing with shortness of breath, fatigue and weakness. The  patient reported that he had still ongoing symptoms (dose number in series 2). On 13Mar2023, he experienced an adverse symptom (dose number In series 2) . He Walked 2 miles home, and when he got home, all day he was totally exhausted (Dose number in series 2). The patient received Non-company suspect vaccine included: influenza vaccine form of admin, route of admin, and batch number were not reported) dose was reported, administered on Dec2022 (3 months ago) for prophylactic vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.